Cargando…
Autophagy inhibition sensitizes LY3023414-induced anti-glioma cell activity in vitro and in vivo
PI3K-AKT-mTOR signaling is a valuable treatment target for human glioma. LY3023414 is a novel, highly-potent and pan PI3K-AKT-mTOR inhibitor. Here, we show that LY3023414 efficiently inhibited survival and proliferation of primary and established human glioma cells. Meanwhile, apoptosis activation w...
Autores principales: | Zheng, Lan, Li, Huanyin, Mo, Yanqing, Qi, Gong, Liu, Bin, Zhao, Jing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5716781/ https://www.ncbi.nlm.nih.gov/pubmed/29228741 http://dx.doi.org/10.18632/oncotarget.22147 |
Ejemplares similares
-
LY3023414 inhibits both osteogenesis and osteoclastogenesis through the PI3K/Akt/GSK3 signalling pathway
por: Chen, Xiaojun, et al.
Publicado: (2021) -
Phase Ib/II Study of Enzalutamide with Samotolisib (LY3023414) or Placebo in Patients with Metastatic Castration-Resistant Prostate Cancer
por: Sweeney, Christopher J., et al.
Publicado: (2022) -
Phase 1 cohort expansion study of LY3023414, a dual PI3K/mTOR inhibitor, in patients with advanced mesothelioma
por: Zauderer, Marjorie G., et al.
Publicado: (2021) -
Phase 1 dose-escalation study of a novel oral PI3K/mTOR dual inhibitor, LY3023414, in patients with cancer
por: Kondo, Shunsuke, et al.
Publicado: (2020) -
Efficacy and safety of abemaciclib alone and with PI3K/mTOR inhibitor LY3023414 or galunisertib versus chemotherapy in previously treated metastatic pancreatic adenocarcinoma: A randomized controlled trial
por: Chiorean, E. Gabriela, et al.
Publicado: (2023)